Details for Patent: 11,524,951
✉ Email this page to a colleague
Which drugs does patent 11,524,951 protect, and when does it expire?
Patent 11,524,951 protects TAGRISSO and is included in one NDA.
This patent has one hundred and thirty-four patent family members in forty-one countries.
Summary for Patent: 11,524,951
| Title: | 2-(2,4,5-substituted-anilino)pyrimidine compounds |
| Abstract: | The present invention relates to certain 2-(2,4,5-substituted-anilino)pyrimidine compounds and pharmaceutically acceptable salts thereof which may be useful in the treatment or prevention of a disease or medical condition mediated through certain mutated forms of epidermal growth factor receptor (for example the L858R activating mutant, the Exon19 deletion activating mutant and the T790M resistance mutant). Such compounds and salts thereof may be useful in the treatment or prevention of a number of different cancers. The invention also relates to pharmaceutical compositions comprising said compounds and salts thereof, especially useful polymorphic forms of these compounds and salts, intermediates useful in the manufacture of said compounds and to methods of treatment of diseases mediated by various different forms of EGFR using said compounds and salts thereof. |
| Inventor(s): | Butterworth Sam, Finlay Maurice Raymond Verschoyle, Ward Richard Andrew, Redfearn Heather Marie, Kadambar Vasantha Krishna, Chintakuntla Chandrasekhara Reddy, Murugan Andiappan, Chuaqui Claudio Edmundo |
| Assignee: | AstraZeneca AB |
| Application Number: | US17096167 |
|
Patent Claim Types: see list of patent claims |
Drugs Protected by US Patent 11,524,951
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | Submissiondate |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Astrazeneca | TAGRISSO | osimertinib mesylate | TABLET;ORAL | 208065-001 | Nov 13, 2015 | RX | Yes | No | ⤷ Try a Trial | ⤷ Try a Trial | Y | Y | ⤷ Try a Trial | |||
| Astrazeneca | TAGRISSO | osimertinib mesylate | TABLET;ORAL | 208065-002 | Nov 13, 2015 | RX | Yes | Yes | ⤷ Try a Trial | ⤷ Try a Trial | Y | Y | ⤷ Try a Trial | |||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Patented / Exclusive Use | >Submissiondate |
International Family Members for US Patent 11,524,951
| Country | Patent Number | Estimated Expiration | Supplementary Protection Certificate | SPC Country | SPC Expiration |
|---|---|---|---|---|---|
| Argentina | 087336 | ⤷ Try a Trial | |||
| Argentina | 115019 | ⤷ Try a Trial | |||
| Australia | 2012288626 | ⤷ Try a Trial | |||
| Brazil | 112014001768 | ⤷ Try a Trial | |||
| >Country | >Patent Number | >Estimated Expiration | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration |
